Fair Value Disclosures [Abstract]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value, Hierarchy [Axis]
Fair Value, Hierarchy [Axis]
Fair Value Hierarchy [Domain]
Fair Value Hierarchy [Domain]
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Inputs, Level 1 [Member]
Significant Other Observable Inputs (Level 2)
Fair Value, Inputs, Level 2 [Member]
Significant Unobservable Inputs (Level 3)
Fair Value, Inputs, Level 3 [Member]
Measurement Frequency [Axis]
Measurement Frequency [Axis]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurement Frequency [Domain]
Fair value, measurements, nonrecurring
Fair Value, Measurements, Nonrecurring [Member]
Asset Class [Axis]
Asset Class [Axis]
Asset Class [Domain]
Asset Class [Domain]
Intangible assets
Intangible Assets [Member]
Intangible Assets [Member]
Certain property, plant and equipment
Property, Plant and Equipment [Member]
Restructuring Plan [Axis]
Restructuring Plan [Axis]
Restructuring Plan [Domain]
Restructuring Plan [Domain]
2017 US Generic Pharmaceuticals Restructuring
US Generic Pharmaceuticals Restructuring 2017 [Member]
US Generic Pharmaceuticals Restructuring 2017 [Member]
Restructuring Type [Axis]
Restructuring Type [Axis]
Type of Restructuring [Domain]
Type of Restructuring [Domain]
Asset impairment charges
Asset Impairment Charges [Member]
Asset Impairment Charges [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restructuring expenses
Restructuring Charges
Assets:
Assets, Fair Value Disclosure [Abstract]
Intangible assets, excluding goodwill
Intangible Assets (Excluding Goodwill), Fair Value Disclosure
Intangible Assets (Excluding Goodwill), Fair Value Disclosure
Certain property, plant and equipment
Property, Plant, and Equipment, Fair Value Disclosure
Total
Assets, Fair Value Disclosure
Total expense for the year
Asset Impairment Charges
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill And Other Intangibles [Table]
Schedule of Goodwill And Other Intangibles [Table]
Schedule of Goodwill and Other Intangibles [Table].
Range [Axis]
Range [Axis]
Range [Domain]
Range [Domain]
Weighted Average
Weighted Average [Member]
Indefinite-lived Intangible Assets [Axis]
Indefinite-lived Intangible Assets [Axis]
Indefinite-lived Intangible Assets, Major Class Name [Domain]
Indefinite-lived Intangible Assets, Major Class Name [Domain]
In-process research and development
In Process Research and Development [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Finite-Lived Intangible Assets by Major Class [Axis]
Finite-Lived Intangible Assets, Major Class Name [Domain]
Finite-Lived Intangible Assets, Major Class Name [Domain]
Licenses
Licensing Agreements [Member]
Tradenames
Trade Names [Member]
Developed technology
Developed Technology Rights [Member]
Other Intangible Assets [Line Items]
Other Intangible Assets [Line Items]
Other Intangible Assets [Line Items]
Cost basis:
Other Intangible Assets, Cost Basis [Abstract]
Other Intangible Assets, Cost Basis [Abstract]
Indefinite-lived intangibles:
Indefinite-lived Intangible Assets [Roll Forward]
Beginning Balance
Indefinite-Lived Intangible Assets (Excluding Goodwill)
Acquisitions
Indefinite-lived Intangible Assets Acquired
Impairments
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Other
Indefinite-lived Intangible Assets, Other
Indefinite-lived Intangible Assets, Other
Effect of Currency Translation
Indefinite-lived Intangible Assets, Foreign Currency Translation Gain (Loss)
Ending Balance
Finite-lived intangibles:
Finite-lived Intangible Assets [Roll Forward]
Beginning Balance
Finite-Lived Intangible Assets, Gross
Acquisitions
Finite-lived Intangible Assets Acquired
Impairments
Impairment of Intangible Assets, Finite-lived
Other
Finite-Lived Intangible Assets, Other
Finite-Lived Intangible Assets, Other
Effect of Currency Translation
Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss)
Ending Balance
Total other intangibles
Intangible Assets, Gross [Roll Forward]
Intangible Assets, Gross [Roll Forward]
Beginning balance
Intangible Assets, Gross (Excluding Goodwill)
Acquisitions
Intangible Assets Acquired
Intangible Assets Acquired
Impairments
Impairment of Intangible Assets (Excluding Goodwill)
Other
Intangible Assets, Other
Intangible Assets, Other
Effect of Currency Translation
Intangible Assets, Foreign Currency Translation Gain (Loss)
Intangible Assets, Foreign Currency Translation Gain (Loss)
Ending balance
Accumulated amortization:
Finite-Lived Intangible Assets, Accumulated Amortization [Roll Forward]
Finite-Lived Intangible Assets, Accumulated Amortization [Roll Forward]
Beginning Balance
Finite-Lived Intangible Assets, Accumulated Amortization
Amortization
Amortization of Intangible Assets
Impairments
Impairment of Intangible Assets, Finite-lived, Effect On Accumulated Amortization
Impairment of Intangible Assets, Finite-lived, Effect On Accumulated Amortization
Other
Finite-Lived Intangible Assets, Other Adjustments, Increase (Decrease) In Accumulated Amortization
Finite-Lived Intangible Assets, Other Adjustments, Increase (Decrease) In Accumulated Amortization
Effect of Currency Translation
Finite-Lived Intangible Assets, Translation Adjustments, Effect On Accumulated Amortization
Finite-Lived Intangible Assets, Translation Adjustments, Effect On Accumulated Amortization
Ending Balance
Net other intangibles
Intangible Assets, Net (Excluding Goodwill)
Intangible life (years)
Finite-Lived Intangible Asset, Useful Life
Business Combinations [Abstract]
ACQUISITIONS
Business Combination Disclosure [Text Block]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Fair Value, Liabilities Measured on Recurring Basis, Disclosure Items [Axis]
Fair Value, Liabilities Measured on Recurring Basis, Disclosure Items [Domain]
Major Types of Debt and Equity Securities [Axis]
Major Types of Debt and Equity Securities [Axis]
Major Types of Debt and Equity Securities [Domain]
Major Types of Debt and Equity Securities [Domain]
Money market funds
Money Market Funds [Member]
Time deposits
Bank Time Deposits [Member]
Equity securities
Equity Securities [Member]
Contingent Consideration by Type [Axis]
Contingent Consideration by Type [Axis]
Contingent Consideration Type [Domain]
Contingent Consideration Type [Domain]
Acquisition-related contingent consideration—short-term
Acquisition Related Contingent Consideration Short Term [Member]
Acquisition Related Contingent Consideration-Short Term [Member]
Acquisition-related contingent consideration—long-term
Acquisition Related Contingent Consideration Long Term [Member]
Acquisition-Related Contingent Consideration-Long Term [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets:
Assets [Abstract]
Fair value of financial assets measured on recurring basis
Assets, Fair Value Disclosure, Recurring
Liabilities:
Liabilities [Abstract]
Fair value of financial liabilities measured on recurring basis
Liabilities, Fair Value Disclosure, Recurring
Accounts Payable and Accrued Liabilities, Current [Abstract]
Accounts Payable And Accrued Expenses
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Earnings Per Share [Abstract]
Numerator:
Earnings Per Share Reconciliation [Abstract]
Loss from continuing operations
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent
Loss from discontinued operations, net of tax
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent
NET LOSS
Net Income (Loss) Attributable to Parent
Denominator:
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
For basic per share data—weighted average shares (shares)
Weighted Average Number of Shares Outstanding, Basic
Dilutive effect of ordinary share equivalents (shares)
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
Dilutive effect of various convertible notes and warrants
Dilutive Effect Of Convertible Senior Subordinated Notes And Warrants
Dilutive Effect Of Convertible Senior Subordinated Notes And Warrants
For diluted per share data—weighted average shares (shares)
Weighted Average Number of Shares Outstanding, Diluted
Equity [Abstract]
OTHER COMPREHENSIVE (LOSS) INCOME
Comprehensive Income (Loss) Note [Text Block]
Schedule of Business Acquisitions, by Acquisition [Table]
Schedule of Business Acquisitions, by Acquisition [Table]
Scenario [Axis]
Scenario [Axis]
Scenario, Unspecified [Domain]
Scenario, Unspecified [Domain]
Forecast
Scenario, Forecast [Member]
Business Acquisition [Axis]
Business Acquisition [Axis]
Business Acquisition, Acquiree [Domain]
Business Acquisition, Acquiree [Domain]
Somerset
Somerset Therapeutics, LLC [Member]
Somerset Therapeutics, LLC [Member]
Other Acquisition
Other Acquisitions [Member]
Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition [Line Items]
Percentage of voting interests acquired
Business Acquisition, Percentage of Voting Interests Acquired
Aggregate consideration transferred
Business Combination, Consideration Transferred
Debt to be assumed
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS AND DIVESTITURES
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]
Debt Disclosure [Abstract]
Schedule of long-term debt instruments
Schedule of Long-term Debt Instruments [Table Text Block]
Segment Reporting [Abstract]
Schedule of reportable segments information
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Schedule of reconciliations of consolidated loss from continuing operations before income tax
Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax To Consolidated Income Before Income Tax [Table Text Block]
Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax To Consolidated Income Before Income Tax [Table Text Block]
Disaggregation of Revenue
Disaggregation of Revenue [Table Text Block]
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Effect of adopting ASC 606
Cumulative Effect of New Accounting Principle in Period of Adoption
Shareholders' equity at January 1, 2018
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance
Net loss
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Other comprehensive loss
Other Comprehensive Income (Loss), Net of Tax
Compensation related to share-based awards
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition
Tax withholding for restricted shares
Adjustments Related to Tax Withholding for Share-based Compensation
Other
Stockholders' Equity, Other
Shareholders' equity, ending balance
Schedule of Long-term Debt Instruments [Table]
Schedule of Long-term Debt Instruments [Table]
Debt Instrument [Axis]
Debt Instrument [Axis]
Debt Instrument, Name [Domain]
Debt Instrument, Name [Domain]
7.25% Senior Notes due 2022
Seven Point Two Five Percent Senior Notes Due Two Thousand Twenty Two [Member]
Seven Point Two Five Percent Senior Notes Due Two Thousand Twenty Two [Member].
5.75% Senior Notes due 2022
Five Point Seven Five Senior Notes Due On Two Thousand Twenty Two [Member]
Five Point Seven Five Senior Notes Due On Two Thousand Twenty Two [Member]
5.375% Senior Notes due 2023
Five Point Three Seven Five Senior Notes Due On Two Thousand Twenty Three [Member]
Five Point Three Seven Five Senior Notes Due On Two Thousand Twenty Three [Member]
6.00% Senior Notes due 2023
Six Point Zero Percent Senior Notes Due Two Thousand Twenty Three [Member]
Six Point Zero Percent Senior Notes Due Two Thousand Twenty Three [Member]
5.875% Senior Secured Notes due 2024
Five Point Eight Seven Five Percent Senior Secured Notes Due Twenty Twenty Four [Member]
Five Point Eight Seven Five Percent Senior Secured Notes Due Twenty Twenty Four [Member]
6.00% Senior Notes due 2025
6.00% Senior Notes Due 2025 [Member]
6.00% Senior Notes Due 2025 [Member]
Term Loan B Facility Due 2024
Term Loan B Facility Due Two Thousand Twenty Four [Member]
Term Loan B Facility Due Two Thousand Twenty Four [Member]
Other debt
Other Debt [Member]
Other Debt [Member]
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Effective interest rate (as percent)
Debt Instrument, Interest Rate, Effective Percentage
Principal Amount
Debt Instrument, Face Amount
Carrying Amount
Long-term Debt
Less current portion, net
Long-term Debt, Current Maturities
Principal amount of total long-term debt, less current portion, net
Debt Instrument, Face Amount, Excluding Current Maturities
Debt Instrument, Face Amount, Excluding Current Maturities
Carrying amount of total long-term debt, less current portion, net
Long-term Debt, Excluding Current Maturities
Interest rate (as percent)
Debt Instrument, Interest Rate, Stated Percentage
Fair value of long term debt
Long-term Debt, Fair Value
Financial assets and liabilities measured at fair value on recurring basis
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Changes to liability for acquisition-related contingent consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Summary of nonrecurring fair value measurements
Fair Value Measurements, Nonrecurring [Table Text Block]
Schedule of tax effects allocated to each component of other comprehensive income
Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]
Schedule of Segment Reporting Information, by Segment [Table]
Schedule of Segment Reporting Information, by Segment [Table]
Consolidation Items [Axis]
Consolidation Items [Axis]
Consolidation Items [Domain]
Consolidation Items [Domain]
Segment Reconciling Items
Segment Reconciling Items [Member]
Operating Segments
Operating Segments [Member]
Inventory Write-Offs
Inventory Write-Offs [Member]
Inventory Write-Offs [Member]
Other restructuring charges
Other Restructuring [Member]
Segment Reporting Information [Line Items]
Segment Reporting Information [Line Items]
Total consolidated loss from continuing operations before income tax
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
Interest expense, net
Interest Income (Expense), Net
Corporate unallocated costs
Segment Reporting Information, Unallocated Corporate Expense
Segment Reporting Information, Unallocated Corporate Expense
Amortization of intangible assets
Inventory step-up
Inventory Step Up
Inventory Step Up
Upfront and milestone payments to partners
Upfront And Milestone Payments To Partners
Upfront and milestone payments to partners.
Separation benefits and other cost reduction initiatives
Cost Reduction Initiatives
Cost Reduction Initiatives
Certain litigation-related and other contingencies, net
Loss Contingency, Loss in Period
Asset impairment charges
Acquisition-related costs
Business Combination, Acquisition Related Costs
Loss on extinguishment of debt
Extinguishment of Debt, Gain (Loss), Net of Tax
Foreign currency impact related to the remeasurement of intercompany debt instruments
Adjustment for Long-term Intercompany Transactions, Gross of Tax
Other, net
Other Nonrecurring (Income) Expense
Severance costs
Severance Costs
Accelerated depreciation
Restructuring and Related Cost, Accelerated Depreciation
Change in fair value of contingent consideration
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability
GOODWILL AND OTHER INTANGIBLES
Goodwill and Intangible Assets Disclosure [Text Block]
Contract with Customer, Asset and Liability [Abstract]
Contract Assets and Liabilities
Contract with Customer, Asset and Liability [Table Text Block]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Award Type [Axis]
Award Type [Axis]
Equity Award [Domain]
Equity Award [Domain]
Nonvested Restricted Stock
Non Vested Restricted Stock [Member]
Non Vested Restricted Stock [Member]
Performance Stock Units
Performance Stock Units [Member]
Performance Stock Units [Member]
Nonvested Stock Options
Non Vested Stock Options [Member]
Non Vested Stock Options [Member]
Plan
Scenario, Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional ordinary shares authorized for issuance (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
Shares issued
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period
Share-based compensation
Share-based Compensation
Share-based compensation awards
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized
Stock options issued (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Awarded in Period, Not Yet Granted, Gross
Share-based Compensation Arrangement by Share-based Payment Award, Options, Awarded in Period, Not Yet Granted, Gross
Target amount of share-based compensation awards (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Awarded in Period, Not Yet Granted
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Awarded in Period, Not Yet Granted
Award fair value (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Weighted average remaining requisite service period, non-vested restricted stock units
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition
Shareholders' (Deficit) Equity
Stockholders' Equity Note Disclosure [Text Block]
Trade accounts payable
Accounts Payable, Trade, Current
Returns and allowances
Accrued Liabilities Returns And Allowances
Accrued liabilities returns and allowances.
Rebates
Accrued Liabilities, Rebates
Accrued Liabilities, Rebates
Chargebacks
Accrued Liabilities Chargebacks
Accrued liabilities chargebacks.
Accrued interest
Interest Payable, Current
Accrued payroll and related benefits
Accrued Employee Benefits, Current
Accrued royalties and other distribution partner payables
Accrued Royalties and Other Distribution Partner Payables, Current
Accrued Royalties and Other Distribution Partner Payables, Current
Acquisition-related contingent consideration—short-term
Business Combination, Contingent Consideration, Liability, Current
Other
Other Accrued Liabilities, Current
Total
Accounts Payable and Accrued Liabilities, Current
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs [Table]
Schedule of Restructuring and Related Costs [Table]
January 2018 Restructuring Initiative
January 2018 Restructuring [Member]
January 2018 Restructuring [Member]
Employee separation, retention and other benefit-related costs
Employee Severence and Other Benefit Related Costs [Member]
Employee Severence and Other Benefit Related Costs [Member]
Other Restructuring Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve [Roll Forward]
Restructuring Reserve [Roll Forward]
Beginning liability balance
Restructuring Reserve
Expenses
Cash distributions
Payments for Restructuring
Ending liability balance
Inventory Disclosure [Abstract]
Schedule of inventory
Schedule of Inventory, Current [Table Text Block]
Disposal Groups, Including Discontinued Operations [Table]
Disposal Groups, Including Discontinued Operations [Table]
Disposal Group Name [Axis]
Disposal Group Name [Axis]
Disposal Group Name [Domain]
Disposal Group Name [Domain]
Litha Healthcare Group Limited
Litha Healthcare Group Limited [Member]
Litha Healthcare Group Limited [Member]
Disposal Group Classification [Axis]
Disposal Group Classification [Axis]
Disposal Group Classification [Domain]
Disposal Group Classification [Domain]
Disposal Group, Held-for-sale, Not Discontinued Operations
Disposal Group, Held-for-sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business, net
Proceeds from Divestiture of Businesses
Consideration receivable
Disposal Group Not Discontinued Operation Consideration Receivable Upon Sale
Disposal Group Not Discontinued Operation Consideration Receivable Upon Sale
Gain on sale of business
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Table]
Equity Components [Axis]
Equity Components [Axis]
Equity Component [Domain]
Equity Component [Domain]
Net unrealized gain (loss) on securities
Accumulated Net Investment Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]
Net unrealized gain (loss) on foreign currency
Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Before Reclassification, Before Tax Amount
Other Comprehensive Income (Loss), before Reclassifications, before Tax
Before Reclassification, Tax Benefit (Expense)
Other Comprehensive Income (Loss) before Reclassifications, Tax
Before Reclassification, Net-of-Tax Amount
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
Reclassification, Before Tax Amount
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax
Reclassification, Tax Benefit (Expense)
Reclassification from AOCI, Current Period, Tax
Reclassification, Net-of-Tax Amount
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax
Before- Tax Amount
Other Comprehensive Income (Loss), before Tax
Tax Benefit (Expense)
Other Comprehensive Income (Loss), Tax
OTHER COMPREHENSIVE (LOSS) INCOME
Income Tax Disclosure [Abstract]
Income tax expense (benefit)
Income Tax Expense (Benefit)
Provisional tax benefit related to Tax Cuts And Jobs Act Of 2017
Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount
Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount
Effective Income Tax Rate Reconciliation, Percent
Effective Income Tax Rate Reconciliation, Percent
License And Collaboration Agreements [Abstract]
License and Collaboration Agreements Abstract
LICENSE AND COLLABORATION AGREEMENTS
Collaborative Arrangement Disclosure [Text Block]
Contract Assets and Liabilities
Revenue from Contract with Customer [Text Block]
Reconciliation of the numerator and denominator of basic and diluted net loss per share
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Statement of Financial Position [Abstract]
ASSETS
CURRENT ASSETS:
Assets, Current [Abstract]
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value
Restricted cash and cash equivalents
Restricted Cash, Current
Accounts receivable
Accounts Receivable, Net, Current
Inventories, net
Inventory, Net
Prepaid expenses and other current assets
Prepaid Expense and Other Assets, Current
Income taxes receivable
Income Taxes Receivable, Current
Total current assets
Assets, Current
MARKETABLE SECURITIES
Marketable Securities, Noncurrent
PROPERTY, PLANT AND EQUIPMENT, NET
Property, Plant and Equipment, Net
GOODWILL
Goodwill
OTHER INTANGIBLES, NET
DEFERRED INCOME TAXES
Deferred Income Tax Assets, Net
OTHER ASSETS
Other Assets, Noncurrent
TOTAL ASSETS
Assets
LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY
Liabilities and Equity [Abstract]
CURRENT LIABILITIES:
Liabilities, Current [Abstract]
Accounts payable and accrued expenses
Current portion of legal settlement accrual
Loss Contingency, Accrual, Current
Current portion of long-term debt
Income taxes payable
Accrued Income Taxes, Current
Total current liabilities
Liabilities, Current
DEFERRED INCOME TAXES
Deferred Income Tax Liabilities, Net
LONG-TERM DEBT, LESS CURRENT PORTION, NET
LONG-TERM LEGAL SETTLEMENT ACCRUAL, LESS CURRENT PORTION
Loss Contingency, Accrual, Noncurrent
OTHER LIABILITIES
Other Liabilities, Noncurrent
COMMITMENTS AND CONTINGENCIES (NOTE 14)
Commitments and Contingencies
SHAREHOLDERS' (DEFICIT) EQUITY:
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Euro deferred shares, $0.01 par value; 4,000,000 shares authorized and issued at both June 30, 2018 and December 31, 2017
Euro Deferred Stock, Value, Issued
Euro Deferred Stock, Value, Issued
Ordinary shares, $0.0001 par value; 1,000,000,000 shares authorized; 223,929,771 and 223,331,706 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively
Common Stock, Value, Issued
Additional paid-in capital
Additional Paid in Capital
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss), Net of Tax
Total shareholders' (deficit) equity
TOTAL LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY
Liabilities and Equity
Disaggregation of Revenue [Table]
Disaggregation of Revenue [Table]
Products and Services [Axis]
Products and Services [Axis]
Products and Services [Domain]
Products and Services [Domain]
XIAFLEX®
Xiaflex [Member]
Xiaflex [Member]
SUPPRELIN® LA
SUPPRELIN LA [Member]
SUPPRELIN LA [Member]
Other Specialty
Other Specialty Products [Member]
Other Specialty Products [Member]
Total Specialty Products
Total Specialty Products [Member]
Total Specialty Products [Member]
PERCOCET®
PERCOCET [Member]
PERCOCET [Member]
VOLTAREN® Gel
Voltaren Gel [Member]
Voltaren Gel [Member]
OPANA® ER
Opana [Member]
Opana [Member]
Other Established
Other Established Products [Member]
Other Established Products [Member]
Total Established Products
Established Products [Member]
Established Products [Member]
Vasostrict®
Vasostrict [Member]
Vasostrict [Member]
ADRENALIN®
Adrenalin [Member]
Adrenalin [Member]
Other Sterile Injectables
Other Sterile Injectables [Member]
Other Sterile Injectables [Member]
Segments [Axis]
Segments [Axis]
Segments [Domain]
Segments [Domain]
U.S. Branded - Specialty & Established Pharmaceuticals
Branded Specialty and Established Pharmaceuticals [Member]
Branded Specialty and Established Pharmaceuticals [Member]
U.S. Branded - Sterile Injectables
Branded Sterile Injectables [Member]
Branded Sterile Injectables [Member]
U.S. Generic Pharmaceuticals
Generic Pharmaceuticals [Member]
Generic Pharmaceuticals [Member]
International Pharmaceuticals
International Pharmaceuticals [Member]
International Pharmaceuticals [Member]
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue [Line Items]
TOTAL REVENUES
Revenues
Product line revenue reporting threshold
Product Line Revenue Reporting Threshold
Product Line Revenue Reporting Threshold
Concentration risk, percentage
Concentration Risk, Percentage
Raw materials
Inventory, Raw Materials, Net of Reserves
Work-in-process
Inventory, Work in Process, Net of Reserves
Finished goods
Inventory, Finished Goods, Net of Reserves
Total
Long-term inventory
Inventory, Noncurrent
Inventories not yet available for sale
Inventory, Not Yet Available For Sale, Net
Inventory, Not Yet Available For Sale, Net
Schedule of changes in stockholders' equity
Schedule of Stockholders Equity [Table Text Block]
Contract assets, net
Contract with Customer, Asset, Net
Contract assets, net - $ change
Contract with Customer, Asset, Increase (Decrease)
Contract with Customer, Asset, Increase (Decrease)
Contract assets, net - % change
Contract with Customer, Asset, Increase (Decrease), Percentage
Contract with Customer, Asset, Increase (Decrease), Percentage
Contract liabilities, net
Contract with Customer, Liability
Contract liabilities, net - $ change
Contract with Customer, Liability, Increase (Decrease)
Contract with Customer, Liability, Increase (Decrease)
Contract liabilities, net - % change
Contract with Customer, Liability, Increase (Decrease), Percentage
Contract with Customer, Liability, Increase (Decrease), Percentage
Contract asset amounts classified as current
Contract with Customer, Asset, Net, Current
Contract liability amounts classified as current
Contract with Customer, Liability, Current
Revenue recognized
Contract with Customer, Liability, Revenue Recognized
Reduction in revenue relating to performance obligation satisfied in prior periods
Contract with Customer, Performance Obligation Satisfied in Previous Period
Goodwill impairment charges
Goodwill, Impairment Loss
Impairment of intangible assets
Somar
Somar [Member]
Somar [Member]
Aggregate purchase price
Disposal Group, Including Discontinued Operation, Consideration
(Gain) loss on sale of business and other assets
Gain (Loss) on Disposition of Assets
Schedule of Accounts Payable and Accrued Liabilities
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]
Accounting Policies [Abstract]
Revenue Recognition
Revenue Recognition, Policy [Policy Text Block]
Recent Accounting Pronouncements
Recent Accounting Pronouncements [Policy Text Block]
Recent Accounting Pronouncements [Text Block]
Statement of Cash Flows [Abstract]
OPERATING ACTIVITIES:
Net Cash Provided by (Used in) Operating Activities [Abstract]
NET LOSS
Adjustments to reconcile Net loss to Net cash provided by operating activities:
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation and amortization
Depreciation, Depletion and Amortization, Nonproduction
Amortization of debt issuance costs and discount
Amortization of Debt Issuance Costs and Discounts
Deferred income taxes
Deferred Income Taxes and Tax Credits
Change in fair value of contingent consideration
Loss on extinguishment of debt
Gain (Loss) on Extinguishment of Debt
Asset impairment charges
Gain on sale of business and other assets
Gain (Loss) on Disposition of Business
Changes in assets and liabilities which provided (used) cash:
Increase (Decrease) in Operating Capital [Abstract]
Accounts receivable
Increase (Decrease) in Accounts Receivable
Inventories
Increase (Decrease) in Inventories
Prepaid and other assets
Increase (Decrease) in Prepaid Expense and Other Assets
Accounts payable, accrued expenses and other liabilities
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Income taxes payable/receivable
Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable
Net cash provided by operating activities
Net Cash Provided by (Used in) Operating Activities
INVESTING ACTIVITIES:
Net Cash Provided by (Used in) Investing Activities [Abstract]
Purchases of property, plant and equipment, excluding capitalized interest
Payments to Acquire Property, Plant, and Equipment
Capitalized interest payments
Interest Paid, Capitalized
Proceeds from sale of business and other assets, net
Other investing activities
Payments for (Proceeds from) Other Investing Activities
Net cash used in investing activities
Net Cash Provided by (Used in) Investing Activities
FINANCING ACTIVITIES:
Net Cash Provided by (Used in) Financing Activities [Abstract]
Proceeds from issuance of notes
Proceeds from Notes Payable
Proceeds from issuance of term loans
Proceeds from Issuance of Debt, Loans
Proceeds from Issuance of Debt, Loans
Principal payments on term loans
Repayments of Other Long-term Debt
Principal payments on other indebtedness
Repayments of Debt
Deferred financing fees
Payments of Financing Costs
Payments for contingent consideration
Payment for Contingent Consideration Liability, Financing Activities
Payments of tax withholding for restricted shares
Payments Related to Tax Withholding for Share-based Compensation
Net cash used in financing activities
Net Cash Provided by (Used in) Financing Activities
Effect of foreign exchange rate
Effect of Exchange Rate on Cash and Cash Equivalents
Movement in cash held for sale
Net Cash Provided by (Used in) Discontinued Operations
NET INCREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD
SUPPLEMENTAL INFORMATION:
Supplemental Cash Flow Information [Abstract]
Cash paid into Qualified Settlement Funds for mesh legal settlements
Settlement Funds, Additions
Settlement Funds, Additions
Cash paid out of Qualified Settlement Funds for mesh legal settlements
Settlement Funds, Payments
Settlement Funds, Payments
Other cash distributions for mesh legal settlements
Other Payments For Legal Settlements
Other Payments For Legal Settlements
SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Accrual for purchases of property, plant and equipment
Capital Expenditures Incurred but Not yet Paid
DEBT
Debt Disclosure [Text Block]
Amortization of intangible assets
Schedule of Goodwill [Table]
Schedule of Goodwill [Table]
Former U.S. Generic Pharmaceuticals
Former U.S. Generic Pharmaceuticals [Member]
Former U.S. Generic Pharmaceuticals [Member]
Goodwill [Line Items]
Goodwill [Line Items]
Accumulated impairment losses
Goodwill, Impaired, Accumulated Impairment Loss
Corporate unallocated costs
Employee Separation, Retention, and Other Benefit Related Costs
Employee Separation, Retention, and Other Benefit Related Costs [Member]
Employee Separation, Retention, and Other Benefit Related Costs [Member]
Restructuring and related cost, expected cost
Restructuring and Related Cost, Expected Cost
Restructuring charges
Restructuring Costs and Asset Impairment Charges
Expected restructuring costs remaining
Restructuring and Related Cost, Expected Cost Remaining
Income Statement [Abstract]
COSTS AND EXPENSES:
Costs and Expenses [Abstract]
Cost of revenues
Cost of Revenue
Selling, general and administrative
Selling, General and Administrative Expense
Research and development
Research and Development Expense
Litigation-related and other contingencies, net
Legal Fees
Acquisition-related and integration items
OPERATING INCOME (LOSS) FROM CONTINUING OPERATIONS
Operating Income (Loss)
INTEREST EXPENSE, NET
LOSS ON EXTINGUISHMENT OF DEBT
OTHER INCOME, NET
Nonoperating Income (Expense)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX
INCOME TAX EXPENSE (BENEFIT)
LOSS FROM CONTINUING OPERATIONS
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
DISCONTINUED OPERATIONS, NET OF TAX (NOTE 3)
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
NET LOSS PER SHARE—BASIC:
Earnings Per Share, Basic [Abstract]
Continuing operations (in dollars per share)
Income (Loss) from Continuing Operations, Per Basic Share
Discontinued operations (in dollars per share)
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share
Basic (in dollars per share)
Earnings Per Share, Basic
NET LOSS PER SHARE—DILUTED:
Earnings Per Share, Diluted [Abstract]
Continuing operations (in dollars per share)
Income (Loss) from Continuing Operations, Per Diluted Share
Discontinued operations (in dollars per share)
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share
Diluted (in dollars per share)
Earnings Per Share, Diluted
WEIGHTED AVERAGE SHARES:
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Basic (shares)
Diluted (shares)
Component of Operating Income [Abstract]
OTHER INCOME, NET
Other Income and Other Expense Disclosure [Text Block]
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES
Commitments and Contingencies Disclosure [Text Block]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Schedule of new accounting pronouncements
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]
FAIR VALUE MEASUREMENTS
Fair Value Disclosures [Text Block]
INCOME TAXES
Income Tax Disclosure [Text Block]
NET LOSS PER SHARE
Earnings Per Share [Text Block]
Loss Contingencies [Table]
Loss Contingencies [Table]
Litigation Status [Axis]
Litigation Status [Axis]
Litigation Status [Domain]
Litigation Status [Domain]
Judicial Ruling
Judicial Ruling [Member]
Legal Entity [Axis]
Legal Entity [Axis]
Entity [Domain]
Entity [Domain]
AMS
American Medical Systems [Member]
American Medical Systems [Member]
Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc. [Member]
Par Pharmaceutical, Inc. [Member]
Endo Pharmaceuticals Inc. and Par Pharmaceuticals Inc.
Endo Pharmaceuticals Inc. and Par Pharmaceuticals Inc. [Member]
Endo Pharmaceuticals Inc. and Par Pharmaceuticals Inc. [Member]
Endo Pharmaceuticals Inc.
Endo Pharmaceuticals Inc. [Member]
Endo Pharmaceuticals Inc. [Member]
Litigation Case [Axis]
Litigation Case [Axis]
Litigation Case [Domain]
Litigation Case [Domain]
Vaginal Mesh Cases
Vaginal Mesh Cases [Member]
Vaginal Mesh Cases [Member]
Testosterone Cases
Testosterone Cases [Member]
Testosterone Cases [Member]
Unapproved Drug Litigation
Unapproved Drug Litigation [Member]
Unapproved Drug Litigation [Member]
Opioid-Related Matters
Opioid-Related Matters [Member]
Opioid-Related Matters [Member]
Pricing Matters Cases
Pricing Matters Cases [Member]
Pricing Matters Cases [Member]
Lidoderm cases
Lidoderm [Member]
Lidoderm [Member]
AndroGel 1.62%
AndroGel 1.62% [Member]
AndroGel 1.62% [Member]
Bier v. Endo International plc, et al.
Bier v. Endo International plc, et al. [Member]
Bier v. Endo International plc, et al. [Member]
VASOSTRICT Related Matters
VASOSTRICT Related Matters [Member]
VASOSTRICT Related Matters [Member]
Title of Individual [Axis]
Title of Individual [Axis]
Relationship to Entity [Domain]
Relationship to Entity [Domain]
Current and Former Directors and Officers
Current and Former Directors and Officers [Member]
Current and Former Directors and Officers [Member]
Subsequent Event Type [Axis]
Subsequent Event Type [Axis]
Subsequent Event Type [Domain]
Subsequent Event Type [Domain]
Subsequent Event
Subsequent Event [Member]
Tranche [Axis]
Tranche [Axis]
Tranche [Axis]
Tranche [Domain]
Tranche [Domain]
[Domain] for Tranche [Axis]
First tranche
Tranche 1 [Member]
Tranche 1 [Member]
Loss Contingencies [Line Items]
Loss Contingencies [Line Items]
Reserve for loss contingencies
Loss Contingency Accrual
Product liability accrual, period expense
Loss Contingency Accrual, Product Liability, Gross
Increase in legal reserves
Loss Contingency Accrual, Period Increase (Decrease)
Loss contingency, claims settled, number
Loss Contingency, Claims Settled, Number
Number of causation theories rejected
Number of Causation Theories Rejected
Number of Causation Theories Rejected
Number of causation theories
Number of Causation Theories
Number of Causation Theories
Payments to plaintiffs and qualified settlement funds
Loss Contingency Accrual, Payments
Settlement funds
Settlement Funds
Settlement Funds
Pending claims, number
Loss Contingency, Pending Claims, Number
Number of cases filed by states
Loss Contingency, Claims Filed By States, Number
Loss Contingency, Claims Filed By States, Number
Number of cases filed by hospitals, health systems, unions, welfare funds or other third-party
Loss Contingency, Number Of Cases Filed By Hospitals, Health Systems, Unions, Welfare Funds Or Other Third-Party
Loss Contingency, Number Of Cases Filed By Hospitals, Health Systems, Unions, Welfare Funds Or Other Third-Party
Number of cases alleging personal injury and/or wrongful death
Loss Contingency, Number Of Cases Alleging Personal Injury And/Or Wrongful Death
Loss Contingency, Number Of Cases Alleging Personal Injury And/Or Wrongful Death
Number of claims set for trial
Loss Contingency, Cases Set For Trial, Number
Loss Contingency, Cases Set For Trial, Number
Number of products involved in claims
Loss Contingency, Number of Products Involved in Claims
Loss Contingency, Number of Products Involved in Claims
Number of tranches for claims
Loss Contingency, Number of Tranches for Claims
Loss Contingency, Number of Tranches for Claims
Number of state attorney generals
State Attorney Generals, Number
State Attorney Generals, Number
Number of claims consolidated
Loss Contingency, Number of Claims Consolidated
Loss Contingency, Number of Claims Consolidated
Number of defendants
Loss Contingency, Number of Defendants
Number of products allegedly manufactured by PPI
Loss Contingency, Number Of Products Allegedly Manufactured By PPI
Loss Contingency, Number Of Products Allegedly Manufactured By PPI
Number of additional defendants
Loss Contingency, Number Of Additional Defendants Named
Loss Contingency, Number Of Additional Defendants Named
Number of patents allegedly infringed upon
Gain Contingency, Patents Allegedly Infringed upon, Number
Number of defendants filing motion to dismiss for lack of personal injury jurisdiction
Loss Contingency, Number Of Defendants Filing Motion To Dismiss, Lack Of Personal Injury Jurisdiction
Loss Contingency, Number Of Defendants Filing Motion To Dismiss, Lack Of Personal Injury Jurisdiction
Number of defendants filing motion to dismiss breach of contract claim
Loss Contingency, Number Of Defendants Filing Motion To Dismiss Breach of Contract Claim
Loss Contingency, Number Of Defendants Filing Motion To Dismiss Breach of Contract Claim
Number of defendants filing motion to dismiss the breach of contract claim
Loss Contingency, Number Of Defendants Filing Motion To Dismiss
Loss Contingency, Number Of Defendants Filing Motion To Dismiss
Stay of litigation, number of days
Loss Contingency, Stay Of Proceedings, Number Of Days
Loss Contingency, Stay Of Proceedings, Number Of Days
Number of patents found infringed upon
Gain Contingency, Patents Found Infringed upon, Number
Period for generic product to be withdrawn
Gain Contingency, Period For Withdrawing Generic Product
Gain Contingency, Period For Withdrawing Generic Product
Number of post-trial motions
Gain Contingency, Number Of Post-Trial Motions
Gain Contingency, Number Of Post-Trial Motions
Settlement awarded
Litigation Settlement, Amount Awarded from Other Party
Lawsuit filing period
Loss Contingency, Lawsuit Filing Period
Loss Contingency, Lawsuit Filing Period
Stay of approval period, hatch-waxman act
Loss Contingency, Stay Of Approval Period, Hatch-Waxman Act
Loss Contingency, Stay Of Approval Period, Hatch-Waxman Act
Schedule of components of other income, net
Schedule of Other Nonoperating Income, by Component [Table Text Block]
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Statement of Comprehensive Income [Abstract]
OTHER COMPREHENSIVE (LOSS) INCOME:
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Net unrealized gain on securities, net of tax:
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax [Abstract]
Unrealized gain arising during the period
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax
Less: reclassification adjustments for (gain) loss realized in net loss
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax
Net unrealized gain (loss) on securities
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax
Net unrealized (loss) gain on foreign currency:
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract]
Foreign currency translation (loss) gain arising during the period
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax
Less: reclassification adjustments for (gain) loss realized in net loss
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax
Foreign currency translation gain (loss)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax
COMPREHENSIVE LOSS
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Number of sterile injectable product candidates
Number of Sterile Injectable Product Candidates
Number of Sterile Injectable Product Candidates
Revenue, Initial Application Period Cumulative Effect Transition [Table]
Revenue, Initial Application Period Cumulative Effect Transition [Table]
Accumulated Deficit
Retained Earnings [Member]
Initial Application Period Cumulative Effect Transition [Axis]
Initial Application Period Cumulative Effect Transition [Axis]
Initial Application Period Cumulative Effect Transition [Domain]
Initial Application Period Cumulative Effect Transition [Domain]
Amounts assuming continued application of ASC 605
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Effect of adoption of ASC 606
Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Adjustments for New Accounting Pronouncements [Axis]
Adjustments for New Accounting Pronouncements [Axis]
Type of Adoption [Domain]
Type of Adoption [Domain]
ASC 606
Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Discount on brand-name drugs
Discount On Brand Name Drugs
Discount On Brand Name Drugs
Decrease to accumulated deficit
Statement of Operations:
OTHER EXPENSE (INCOME), NET
(Loss) income from continuing operations
Basic (in dollars per share)
Net (loss) income per share—Diluted:
Diluted (in dollars per share)
Statement of Financial Position [Abstract]
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Shareholders' (deficit) equity:
Statement of Stockholders' Equity [Abstract]
Loss Contingency Nature [Axis]
Loss Contingency Nature [Axis]
Loss Contingency, Nature [Domain]
Loss Contingency, Nature [Domain]
Mesh Product Liability Accrual
Product Liability [Member]
Product Liability [Member]
Qualified Settlement Funds
Settlement Funds [Roll Forward]
Settlement Funds [Roll Forward]
Beginning balance
Cash contributions to Qualified Settlement Funds
Cash distributions to settle disputes from Qualified Settlement Funds
Settlement Funds, Payments To Plaintiff Counsel From Qualified Settlement Funds
Settlement Funds, Payments To Plaintiff Counsel From Qualified Settlement Funds
Other (1)
Settlement Funds, Other
Settlement Funds, Other
Ending balance
Mesh Liability Accrual
Loss Contingency Accrual [Roll Forward]
Beginning balance
Additional charges
Loss Contingency Accrual, Provision
Cash distributions to settle disputes from Qualified Settlement Funds
Loss Contingency Accrual, Payments To Plaintiff Counsel From Qualified Settlement Funds
Loss Contingency Accrual, Payments To Plaintiff Counsel From Qualified Settlement Funds
Cash distributions to settle disputes
Loss Contingency Accrual, Payments To Plaintiff Counsel
Loss Contingency Accrual, Payments To Plaintiff Counsel
Ending balance
New Accounting Pronouncements or Change in Accounting Principle [Table]
New Accounting Pronouncements or Change in Accounting Principle [Table]
Accounting Standards Update 2016-18
Accounting Standards Update 2016-18 [Member]
Prior to Adoption
Scenario, Previously Reported [Member]
Impact of Adoption
Restatement Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net cash provided by operating activities
Net cash used in investing activities
Net cash used in financing activities
Net change
Cash and Cash Equivalents, Period Increase (Decrease)
Line of Credit Facility [Table]
Line of Credit Facility [Table]
Credit Facility [Axis]
Credit Facility [Axis]
Credit Facility [Domain]
Credit Facility [Domain]
Revolving Credit Facility
Revolving Credit Facility [Member]
Long-term Debt, Type [Axis]
Long-term Debt, Type [Axis]
Long-term Debt, Type [Domain]
Long-term Debt, Type [Domain]
Line of Credit Facility [Line Items]
Line of Credit Facility [Line Items]
Credit facility, remaining borrowing capacity
Line of Credit Facility, Remaining Borrowing Capacity
Schedule of changes in the carrying amount of goodwill
Schedule of Goodwill [Table Text Block]
Schedule of other intangible assets
Schedule Of Other Intangible Assets [Table Text Block]
Schedule of other intangible assets table text block
Schedule of future amortization expense
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
Schedule of intangible asset impairment charges including goodwill
Schedule of Intangible Asset Impairment Charges Including Goodwill [Table Text Block]
Schedule of Intangible Asset Impairment Charges Including Goodwill [Table Text Block]
Document And Entity Information [Abstract]
Document and Entity Information [Abstract]
Document Type
Document Type
Amendment Flag
Amendment Flag
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Trading Symbol
Trading Symbol
Entity Registrant Name
Entity Registrant Name
Entity Central Index Key
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Entity Filer Category
Entity Filer Category
Entity Ordinary Shares Outstanding
Entity Common Stock, Shares Outstanding
Changes in Qualified Settlement Funds accounts and product liability balance
Schedule of Loss Contingencies by Contingency [Table Text Block]
Acquisition-related contingent consideration
Acquisition Related Contingent Consideration [Member]
Acquisition-Related Contingent Consideration [Member]
Auxilium acquisition
Auxilium Pharmaceuticals, Inc. [Member]
Auxilium Pharmaceuticals, Inc. [Member]
Lehigh Valley Technologies, Inc. acquisitions
Lehigh Valley Technologies, Inc. [Member]
Lehigh Valley Technologies, Inc. [Member]
VOLTAREN® Gel acquisition
Other
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value
Amounts settled
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Changes in fair value recorded in earnings
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Effect of currency translation
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Gain (Loss) Included in Other Comprehensive Income (Loss)
Fair Value Adjustments and Accretion
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments And Accretion
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments And Accretion
Payments and Other
Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements And Effect Of Currency Translation
Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements And Effect Of Currency Translation
End of period
Number of reportable segments
Number of Reportable Segments
Total net revenues from external customers
Total segment adjusted income from continuing operations before income tax
Adjusted Income (Loss) Before Income Tax
Adjusted income (loss) before income tax.
2018
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year
2019
Finite-Lived Intangible Assets, Amortization Expense, Year Two
2020
Finite-Lived Intangible Assets, Amortization Expense, Year Three
2021
Finite-Lived Intangible Assets, Amortization Expense, Year Four
2022
Finite-Lived Intangible Assets, Amortization Expense, Year Five
Euro deferred shares, par value (in dollars per share)
Euro Deferred Shares, Par or Stated Value Per Share
Euro Deferred Shares, Par or Stated Value Per Share
Euro deferred shares, shares authorized
Euro Deferred Shares, Shares Authorized
Euro Deferred Shares, Shares Authorized
Euro deferred shares, shares issued
Euro Deferred Shares, Shares Issued
Euro Deferred Shares, Shares Issued
Common stock, par value (in dollars per share)
Common Stock, Par or Stated Value Per Share
Common stock, shares authorized
Common Stock, Shares Authorized
Common stock, shares issued
Common Stock, Shares, Issued
Common stock, shares outstanding
Common Stock, Shares, Outstanding
Schedule of disposal groups, including discontinued operations, income statement, balance sheet and additional disclosures
Disposal Groups, Including Discontinued Operations [Table Text Block]
RESTRUCTURING
Restructuring and Related Activities Disclosure [Text Block]
In process research and development or developed technology
In Process Research and Development Or Developed Technology [Member]
In Process Research and Development Or Developed Technology [Member]
U.S. Branded - Specialty & Established Pharmaceuticals
Branded Pharmaceuticals [Member]
Branded Pharmaceuticals [Member]
Paladin Labs Inc.
Paladin Labs Inc. [Member]
Paladin Labs Inc. [Member]
Serelaxin In-Process Research and Development Intangible Assets
Serelaxin In-Process Research and Development Intangible Assets [Member]
Serelaxin In-Process Research and Development Intangible Assets [Member]
Discount rate applied (percent)
Fair Value Inputs, Discount Rate
Goodwill impairment charges (reduction)
Non-cash intangible asset impairment charge
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Investment Type [Axis]
Investment Type [Axis]
Investments [Domain]
Investments [Domain]
Restricted cash and cash equivalents
Restricted Cash And Cash Equivalents [Member]
Restricted Cash And Cash Equivalents [Member]
Minimum
Minimum [Member]
Maximum
Maximum [Member]
Restricted cash and cash equivalents
Restricted Cash and Cash Equivalents
Restricted cash and cash equivalents classified as current assets
Discount rate range (percent)
Goodwill impairment charges
Schedule of Income Tax
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
Goodwill [Roll Forward]
Goodwill [Roll Forward]
Goodwill, beginning balance
Allocation to current segments
Goodwill, Allocation To Current Segments
Goodwill, Allocation To Current Segments
Effect of currency translation on gross balance
Goodwill, Foreign Currency Translation Gain (Loss)
Goodwill impairment charges
Goodwill, ending balance
Foreign currency gain, net
Foreign Currency Transaction Gain (Loss), before Tax
Equity (earnings) loss from investments accounted for under the equity method, net
Income (Loss) from Equity Method Investments
Other miscellaneous, net
Other Nonoperating Income (Expense)
Other income, net
Schedule of restructuring reserve by type of cost
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]
January 2017 Restructuring
January 2017 Restructuring [Member]
January 2017 Restructuring [Member]
Accelerated Depreciation
Accelerated Depreciation [Member]
Accelerated Depreciation [Member]
Asset Impairment Charges
Inventory Reserve
Inventory Valuation Reserve [Member]
Expected number of positions to be eliminated
Restructuring and Related Cost, Expected Number of Positions Eliminated
INVENTORIES
Inventory Disclosure [Text Block]
SEGMENT RESULTS
Segment Reporting Disclosure [Text Block]
Discontinued Operations, Disposed of by Sale
Discontinued Operations, Disposed of by Sale [Member]
Astora
Astora [Member]
Astora [Member]
Litigation-related and other contingencies, net
Disposal Group Including Discontinued Operation, Litigation Related And Other Contingencies
Disposal Group Including Discontinued Operation, Litigation Related And Other Contingencies
Loss from discontinued operations before income taxes
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax
Income tax benefit
Discontinued Operation, Tax Effect of Discontinued Operation
Income (loss) from discontinued operations, net of tax
Cash used in discontinued investing activities Operations
Cash Provided by (Used in) Investing Activities, Discontinued Operations
Depreciation and amortization
Disposal Group, Including Discontinued Operation, Depreciation and Amortization